Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 23 of 23 entries
Sorted by: Best Match Show Resources per page
Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI.

Case reports in oncological medicine

Nikolaou C, Matikas A, Papavasilopoulou M, Mavroudis D, Vamvakas L.
PMID: 26090249
Case Rep Oncol Med. 2015;2015:659624. doi: 10.1155/2015/659624. Epub 2015 May 21.

Metastatic pancreatic adenocarcinoma confers a poor prognosis. Even with recent advances in the treatment of this disease with the introduction of two modestly effective chemotherapy regimens, complete responses are still very rare. Moreover, there are no published data on...

Cite
Nikolaou C, Matikas A, Papavasilopoulou M, et al. Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI. Case Rep Oncol Med. 2015;2015:659624doi: 10.1155/2015/659624.
Nikolaou, C., Matikas, A., Papavasilopoulou, M., Mavroudis, D., & Vamvakas, L. (2015). Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI. Case reports in oncological medicine, 2015659624. https://doi.org/10.1155/2015/659624
Nikolaou, Christos, et al. "Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI." Case reports in oncological medicine vol. 2015 (2015): 659624. doi: https://doi.org/10.1155/2015/659624
Nikolaou C, Matikas A, Papavasilopoulou M, Mavroudis D, Vamvakas L. Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI. Case Rep Oncol Med. 2015;2015:659624. doi: 10.1155/2015/659624. Epub 2015 May 21. PMID: 26090249; PMCID: PMC4454729.
Copy Download .nbib Format: NLM
The contribution of transgenic plants to better health through improved nutrition: opportunities and constraints.

Genes & nutrition

Pérez-Massot E, Banakar R, Gómez-Galera S, Zorrilla-López U, Sanahuja G, Arjó G, Miralpeix B, Vamvaka E, Farré G, Rivera SM, Dashevskaya S, Berman J, Sabalza M, Yuan D, Bai C, Bassie L, Twyman RM, Capell T, Christou P, Zhu C.
PMID: 22926437
Genes Nutr. 2013 Jan;8(1):29-41. doi: 10.1007/s12263-012-0315-5. Epub 2012 Aug 29.

Malnutrition is a prevalent and entrenched global socioeconomic challenge that reflects the combined impact of poverty, poor access to food, inefficient food distribution infrastructure, and an over-reliance on subsistence mono-agriculture. The dependence on staple cereals lacking many essential nutrients...

Cite
Pérez-Massot E, Banakar R, Gómez-Galera S, et al. The contribution of transgenic plants to better health through improved nutrition: opportunities and constraints. Genes Nutr. 2012;8(1):29-41doi: 10.1007/s12263-012-0315-5.
Pérez-Massot, E., Banakar, R., Gómez-Galera, S., Zorrilla-López, U., Sanahuja, G., Arjó, G., Miralpeix, B., Vamvaka, E., Farré, G., Rivera, S. M., Dashevskaya, S., Berman, J., Sabalza, M., Yuan, D., Bai, C., Bassie, L., Twyman, R. M., Capell, T., Christou, P., & Zhu, C. (2013). The contribution of transgenic plants to better health through improved nutrition: opportunities and constraints. Genes & nutrition, 8(1), 29-41. https://doi.org/10.1007/s12263-012-0315-5
Pérez-Massot, Eduard, et al. "The contribution of transgenic plants to better health through improved nutrition: opportunities and constraints." Genes & nutrition vol. 8,1 (2013): 29-41. doi: https://doi.org/10.1007/s12263-012-0315-5
Pérez-Massot E, Banakar R, Gómez-Galera S, Zorrilla-López U, Sanahuja G, Arjó G, Miralpeix B, Vamvaka E, Farré G, Rivera SM, Dashevskaya S, Berman J, Sabalza M, Yuan D, Bai C, Bassie L, Twyman RM, Capell T, Christou P, Zhu C. The contribution of transgenic plants to better health through improved nutrition: opportunities and constraints. Genes Nutr. 2013 Jan;8(1):29-41. doi: 10.1007/s12263-012-0315-5. Epub 2012 Aug 29. PMID: 22926437; PMCID: PMC3534993.
Copy Download .nbib Format: NLM
Voxel based internal dosimetry during radionuclide therapy.

Hellenic journal of nuclear medicine

Vamvakas I, Lyra M.
PMID: 26665215
Hell J Nucl Med. 2015 Sep-Dec;18:76-80.

BACKGROUND: Many radionuclides have been used for several decades in cancer treatment. (131)I, (90)Y, (89)Sr, (111)In, (177)Lu and (223)Ra are some of the most widely used radioisotopes. Therapeutic results and side effects can be associated only if the absorbed...

Cite
Vamvakas I, Lyra M. Voxel based internal dosimetry during radionuclide therapy. Hell J Nucl Med. 2015;18:76-80
Vamvakas, I., & Lyra, M. (2015). Voxel based internal dosimetry during radionuclide therapy. Hellenic journal of nuclear medicine, 1876-80.
Vamvakas, Ioannis, and Lyra, Maria. "Voxel based internal dosimetry during radionuclide therapy." Hellenic journal of nuclear medicine vol. 18 (2015): 76-80.
Vamvakas I, Lyra M. Voxel based internal dosimetry during radionuclide therapy. Hell J Nucl Med. 2015 Sep-Dec;18:76-80. PMID: 26665215.
Copy Download .nbib Format: NLM
Mesothelial cyst of the round ligament misdiagnosed as irreducible inguinal hernia.

Case reports in surgery

Manatakis DK, Stamos N, Agalianos C, Vamvakas P, Kordelas A, Davides D.
PMID: 24159409
Case Rep Surg. 2013;2013:408078. doi: 10.1155/2013/408078. Epub 2013 Sep 18.

We report the case of a 36-year-old woman who presented with signs and symptoms of an irreducible inguinal hernia. Surgical exploration revealed a mesothelial cyst of the round ligament of the uterus. Mesothelial cysts of the round ligament are...

Cite
Manatakis DK, Stamos N, Agalianos C, et al. Mesothelial cyst of the round ligament misdiagnosed as irreducible inguinal hernia. Case Rep Surg. 2013;2013:408078doi: 10.1155/2013/408078.
Manatakis, D. K., Stamos, N., Agalianos, C., Vamvakas, P., Kordelas, A., & Davides, D. (2013). Mesothelial cyst of the round ligament misdiagnosed as irreducible inguinal hernia. Case reports in surgery, 2013408078. https://doi.org/10.1155/2013/408078
Manatakis, Dimitrios K, et al. "Mesothelial cyst of the round ligament misdiagnosed as irreducible inguinal hernia." Case reports in surgery vol. 2013 (2013): 408078. doi: https://doi.org/10.1155/2013/408078
Manatakis DK, Stamos N, Agalianos C, Vamvakas P, Kordelas A, Davides D. Mesothelial cyst of the round ligament misdiagnosed as irreducible inguinal hernia. Case Rep Surg. 2013;2013:408078. doi: 10.1155/2013/408078. Epub 2013 Sep 18. PMID: 24159409; PMCID: PMC3789490.
Copy Download .nbib Format: NLM
Digital technologies for medicines: shaping a framework for success.

Nature reviews. Drug discovery

Cerreta F, Ritzhaupt A, Metcalfe T, Askin S, Duarte J, Berntgen M, Vamvakas S.
PMID: 32398879
Nat Rev Drug Discov. 2020 Sep;19(9):573-574. doi: 10.1038/d41573-020-00080-6.

No abstract available.

Cite
Cerreta F, Ritzhaupt A, Metcalfe T, et al. Digital technologies for medicines: shaping a framework for success. Nat Rev Drug Discov. 2020;19(9):573-574doi: 10.1038/d41573-020-00080-6.
Cerreta, F., Ritzhaupt, A., Metcalfe, T., Askin, S., Duarte, J., Berntgen, M., & Vamvakas, S. (2020). Digital technologies for medicines: shaping a framework for success. Nature reviews. Drug discovery, 19(9), 573-574. https://doi.org/10.1038/d41573-020-00080-6
Cerreta, Francesca, et al. "Digital technologies for medicines: shaping a framework for success." Nature reviews. Drug discovery vol. 19,9 (2020): 573-574. doi: https://doi.org/10.1038/d41573-020-00080-6
Cerreta F, Ritzhaupt A, Metcalfe T, Askin S, Duarte J, Berntgen M, Vamvakas S. Digital technologies for medicines: shaping a framework for success. Nat Rev Drug Discov. 2020 Sep;19(9):573-574. doi: 10.1038/d41573-020-00080-6. PMID: 32398879.
Copy Download .nbib Format: NLM
Post-Traumatic Stress Disorder and Burnout in Healthcare Professionals During the SARS-CoV-2 Pandemic: a Cross-Sectional Study.

Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures)

Ilias I, Mantziou V, Vamvakas E, Kampisiouli E, Theodorakopoulou M, Vrettou C, Douka E, Vassiliou AG, Orfanos S, Kotanidou A, Dimopoulou I.
PMID: 34722899
J Crit Care Med (Targu Mures). 2021 Jan 29;7(1):14-20. doi: 10.2478/jccm-2020-0042. eCollection 2021 Jan.

INTRODUCTION: Healthcare professionals who are directly involved in the diagnosis, treatment, and general care of patients with SARS-CoV-2 are at risk of developing adverse psychological reactions. A cross-sectional study of healthcare professionals aimed to determine the impact of the...

Cite
Ilias I, Mantziou V, Vamvakas E, et al. Post-Traumatic Stress Disorder and Burnout in Healthcare Professionals During the SARS-CoV-2 Pandemic: a Cross-Sectional Study. J Crit Care Med (Targu Mures). 2021;7(1):14-20doi: 10.2478/jccm-2020-0042.
Ilias, I., Mantziou, V., Vamvakas, E., Kampisiouli, E., Theodorakopoulou, M., Vrettou, C., Douka, E., Vassiliou, A. G., Orfanos, S., Kotanidou, A., & Dimopoulou, I. (2021). Post-Traumatic Stress Disorder and Burnout in Healthcare Professionals During the SARS-CoV-2 Pandemic: a Cross-Sectional Study. Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures), 7(1), 14-20. https://doi.org/10.2478/jccm-2020-0042
Ilias, Ioannis, et al. "Post-Traumatic Stress Disorder and Burnout in Healthcare Professionals During the SARS-CoV-2 Pandemic: a Cross-Sectional Study." Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) vol. 7,1 (2021): 14-20. doi: https://doi.org/10.2478/jccm-2020-0042
Ilias I, Mantziou V, Vamvakas E, Kampisiouli E, Theodorakopoulou M, Vrettou C, Douka E, Vassiliou AG, Orfanos S, Kotanidou A, Dimopoulou I. Post-Traumatic Stress Disorder and Burnout in Healthcare Professionals During the SARS-CoV-2 Pandemic: a Cross-Sectional Study. J Crit Care Med (Targu Mures). 2021 Jan 29;7(1):14-20. doi: 10.2478/jccm-2020-0042. eCollection 2021 Jan. PMID: 34722899; PMCID: PMC8519377.
Copy Download .nbib Format: NLM
Cyclin D1 and Rb protein expression and their correlation with prognosis in patients with colon cancer.

World journal of surgical oncology

Kouraklis G, Theocharis S, Vamvakas P, Vagianos C, Glinavou A, Giaginis C, Sioka C.
PMID: 16426443
World J Surg Oncol. 2006 Jan 20;4:5. doi: 10.1186/1477-7819-4-5.

BACKGROUND: Cyclin D1 plays a major role as a potential contributor to the multistep process of oncogenesis; nevertheless its prognostic significance in colon cancer has already been examined in a few studies and needs to be further delineated. The...

Cite
Kouraklis G, Theocharis S, Vamvakas P, et al. Cyclin D1 and Rb protein expression and their correlation with prognosis in patients with colon cancer. World J Surg Oncol. 2006;4:5doi: 10.1186/1477-7819-4-5.
Kouraklis, G., Theocharis, S., Vamvakas, P., Vagianos, C., Glinavou, A., Giaginis, C., & Sioka, C. (2006). Cyclin D1 and Rb protein expression and their correlation with prognosis in patients with colon cancer. World journal of surgical oncology, 45. https://doi.org/10.1186/1477-7819-4-5
Kouraklis, Gregory, et al. "Cyclin D1 and Rb protein expression and their correlation with prognosis in patients with colon cancer." World journal of surgical oncology vol. 4 (2006): 5. doi: https://doi.org/10.1186/1477-7819-4-5
Kouraklis G, Theocharis S, Vamvakas P, Vagianos C, Glinavou A, Giaginis C, Sioka C. Cyclin D1 and Rb protein expression and their correlation with prognosis in patients with colon cancer. World J Surg Oncol. 2006 Jan 20;4:5. doi: 10.1186/1477-7819-4-5. PMID: 16426443; PMCID: PMC1360071.
Copy Download .nbib Format: NLM
Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.

Case reports in oncology

Saloustros E, Androulakis N, Vamvakas L, Mavroudis D, Georgoulias V.
PMID: 21537380
Case Rep Oncol. 2010 Oct 12;3(3):368-71. doi: 10.1159/000321630.

Nephrotic-range proteinuria, which denotes structural damage to the glomerular filtration barrier, occurs in 1-2% of bevacizumab-treated patients. The glomerular injury and subsequent proteinuria is probably due to a direct targeting of vascular endothelial growth factor (VEGF). We report a...

Cite
Saloustros E, Androulakis N, Vamvakas L, et al. Favorable clinical course of patients experiencing bevacizumab-induced proteinuria. Case Rep Oncol. 2010;3(3):368-71doi: 10.1159/000321630.
Saloustros, E., Androulakis, N., Vamvakas, L., Mavroudis, D., & Georgoulias, V. (2010). Favorable clinical course of patients experiencing bevacizumab-induced proteinuria. Case reports in oncology, 3(3), 368-71. https://doi.org/10.1159/000321630
Saloustros, Emmanouil, et al. "Favorable clinical course of patients experiencing bevacizumab-induced proteinuria." Case reports in oncology vol. 3,3 (2010): 368-71. doi: https://doi.org/10.1159/000321630
Saloustros E, Androulakis N, Vamvakas L, Mavroudis D, Georgoulias V. Favorable clinical course of patients experiencing bevacizumab-induced proteinuria. Case Rep Oncol. 2010 Oct 12;3(3):368-71. doi: 10.1159/000321630. PMID: 21537380; PMCID: PMC3085070.
Copy Download .nbib Format: NLM
Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation.

Clinical pharmacology and therapeutics

Eichler HG, Koenig F, Arlett P, Enzmann H, Humphreys A, Pétavy F, Schwarzer-Daum B, Sepodes B, Vamvakas S, Rasi G.
PMID: 31574163
Clin Pharmacol Ther. 2020 Apr;107(4):773-779. doi: 10.1002/cpt.1638. Epub 2019 Oct 01.

Real-world data and patient-level data from completed randomized controlled trials are becoming available for secondary analysis on an unprecedented scale. A range of novel methodologies and study designs have been proposed for their analysis or combination. However, to make...

Cite
Eichler HG, Koenig F, Arlett P, et al. Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation. Clin Pharmacol Ther. 2019;107(4):773-779doi: 10.1002/cpt.1638.
Eichler, H. G., Koenig, F., Arlett, P., Enzmann, H., Humphreys, A., Pétavy, F., Schwarzer-Daum, B., Sepodes, B., Vamvakas, S., & Rasi, G. (2020). Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation. Clinical pharmacology and therapeutics, 107(4), 773-779. https://doi.org/10.1002/cpt.1638
Eichler, Hans-Georg, et al. "Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation." Clinical pharmacology and therapeutics vol. 107,4 (2020): 773-779. doi: https://doi.org/10.1002/cpt.1638
Eichler HG, Koenig F, Arlett P, Enzmann H, Humphreys A, Pétavy F, Schwarzer-Daum B, Sepodes B, Vamvakas S, Rasi G. Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation. Clin Pharmacol Ther. 2020 Apr;107(4):773-779. doi: 10.1002/cpt.1638. Epub 2019 Oct 01. PMID: 31574163; PMCID: PMC7158212.
Copy Download .nbib Format: NLM
Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.

Annals of gastroenterology

Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J.
PMID: 29333068
Ann Gastroenterol. 2018 Jan-Feb;31(1):65-70. doi: 10.20524/aog.2017.0215. Epub 2017 Nov 27.

BACKGROUND: This study evaluated the safety and efficacy of nab-paclitaxel as second-line treatment in patients with advanced gastric adenocarcinoma.METHODS: Thirty-nine pretreated patients [33 with taxane-based regimens (docetaxel, cisplatin, and fluorouracil)] and 6 with combination of fluoropyrimidines plus cisplatin with...

Cite
Katsaounis P, Kotsakis A, Kentepozidis N, et al. Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group. Ann Gastroenterol. 2017;31(1):65-70doi: 10.20524/aog.2017.0215.
Katsaounis, P., Kotsakis, A., Kentepozidis, N., Polyzos, A., Bakogeorgos, M., Koinis, F., Vamvakas, L., Vardakis, N., Kalbakis, K., Boukovinas, I., Varthalitis, I. I., Prinarakis, E., Georgoulias, V., & Souglakos, J. (2018). Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group. Annals of gastroenterology, 31(1), 65-70. https://doi.org/10.20524/aog.2017.0215
Katsaounis, Panagiotis, et al. "Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group." Annals of gastroenterology vol. 31,1 (2018): 65-70. doi: https://doi.org/10.20524/aog.2017.0215
Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J. Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group. Ann Gastroenterol. 2018 Jan-Feb;31(1):65-70. doi: 10.20524/aog.2017.0215. Epub 2017 Nov 27. PMID: 29333068; PMCID: PMC5759614.
Copy Download .nbib Format: NLM
MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer.

Biomedicines

Papadaki C, Thomopoulou K, Monastirioti A, Koronakis G, Papadaki MA, Rounis K, Vamvakas L, Nikolaou C, Mavroudis D, Agelaki S.
PMID: 33924670
Biomedicines. 2021 Apr 13;9(4). doi: 10.3390/biomedicines9040421.

MicroRNAs (miRNAs) are involved in the regulation of immune response and hold an important role in tumor immune escape. We investigated the differential expression of the immunomodulatory miR-10b, miR-19a, miR-20a, miR-126, and miR-155 in the plasma of healthy women...

Cite
Papadaki C, Thomopoulou K, Monastirioti A, et al. MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer. Biomedicines. 2021;9(4)doi: 10.3390/biomedicines9040421.
Papadaki, C., Thomopoulou, K., Monastirioti, A., Koronakis, G., Papadaki, M. A., Rounis, K., Vamvakas, L., Nikolaou, C., Mavroudis, D., & Agelaki, S. (2021). MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer. Biomedicines, 9(4), . https://doi.org/10.3390/biomedicines9040421
Papadaki, Chara, et al. "MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer." Biomedicines vol. 9,4 (2021). doi: https://doi.org/10.3390/biomedicines9040421
Papadaki C, Thomopoulou K, Monastirioti A, Koronakis G, Papadaki MA, Rounis K, Vamvakas L, Nikolaou C, Mavroudis D, Agelaki S. MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer. Biomedicines. 2021 Apr 13;9(4). doi: 10.3390/biomedicines9040421. PMID: 33924670; PMCID: PMC8069787.
Copy Download .nbib Format: NLM
Showing 13 to 23 of 23 entries